Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTC4S | Q16873 | 20/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27850786 | 0.75 | LTC4S (0.38) | LTC4S | |
| SCHEMBL231541 | 0.72 | LTC4S (0.39) | LTC4S | |
| SCHEMBL733566 | 0.68 | — | — | |
| SCHEMBL4005376 | 0.66 | LTA4H (0.43) | — | |
| SCHEMBL15198856 | 0.64 | KCNJ1 (0.39) | — | |
| SCHEMBL8196798 | 0.64 | KCNH2 (0.54) | — | |
| SCHEMBL24991834 | 0.63 | ALDH1A1 (0.55) | — | |
| SCHEMBL230230 | 0.63 | KDM4E (0.38) | — | |
| SCHEMBL20489961 | 0.63 | PARP15 (0.45) | — | |
| SCHEMBL19606195 | 0.63 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035358-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SE) | 2013-02-07 | — | — | US | disclosed |
| EP-2545036-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2013-01-16 | — | — | EP | disclosed |
| EP-2406220-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| WO-2011110824-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2010103279-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS | BIOLIPOX AB (SE) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035358-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885 |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | LTC4S 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.